Adalimumab biosimilar exhibits same efficacy and safety for rheumatoid arthritis as originator
![Rheumatoid arthritis](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20100%2056%22%3E%3C/svg%3E)
Patients with rheumatoid arthritis who switched from adalimumab (Humira) to its biosimilar, adalimumab-adbm (Cyltezo), saw no clinically meaningful difference, according to the results of a 48-week Phase III clinical trial…